

RECEIVED  
CENTRAL FAX CENTER

AUG 08 2006

**REMARKS**

Claims 126, 128-145 were pending in the present application. Applicants have amended claim 126 and 128-145 to clarify that they are directed to pharmaceutical tablets instead of pharmaceutical compositions. Support for such amendments can be found, *inter alia*, on page 32, line 29 and on page 33, line 1-6 of the original specification. Applicants respectfully submit that the present Amendment is fully supported by the original specification and does not raise any issue of new matter. Therefore, entry of the present Amendment is respectfully requested. Upon entry of the present Amendment and the acceptance of the RCE, claims 126, 128-145 will be under continued examination.

**CONCLUSION**

In view of the claim amendments and the remarks, further and favorable consideration of all pending claims are respectfully requested.

It is believed that no fee, other the RCE fee, is deemed necessary in connection with the filing of the present Amendment. However, if any fees are required, the Commissioner is hereby authorized to charge any such fees to our Deposit Account No. 16-1445.

Respectfully submitted,

Date: Aug. 8, 2006

Lance Y. Liu  
Lance Y. Liu  
Attorney for Applicant(s)  
Reg. No. 45,379

**Customer No. 28523**

Pfizer Inc.  
Patent Department, MS 8260-1611  
Eastern Point Road  
Groton, Connecticut 06340  
(860) 686-1652